| Name | Title | Contact Details |
|---|
InnovaSystems is a Pennsauken, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our first-of-its-kind software system lets clinical research investigators create e-source templates and use a mobile tablet to capture source data. Research sites can save time, improve accuracy and reduce protocol deviations through our autofill and data validation techniques. Our system also has patient scheduling, recruiting and financial management for a holistic, all-in-one enterprise solution.
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. Galmed Pharmaceuticals Galmed’s business has been, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABAC’s and NASH.
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.